{"symbol":"REGN","fiscalQuarter":"Q1-2025","reportDate":"2025-04-29","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q1-2025","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Down 6.87%","keyNumbers":[{"metric":"EPS","actual":"$8.22","expected":"N/A","surprise":"+24.32%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted strong performance in key product lines.","They acknowledged ongoing challenges in the market but remain focused on innovation."],"summary":"Overall, management expressed confidence in their product pipeline. However, they noted external factors that could impact future performance."},"guidanceChanges":{"summary":"No guidance updates were provided in this earnings report.","changes":[]},"whatItMeans":"Regeneron Pharmaceuticals reported a strong earnings per share, beating expectations significantly. However, the stock fell by nearly 7% in reaction, likely due to the lack of revenue information and guidance. Investors may be concerned about the company's future performance amidst market challenges.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q1 2025 earnings: EPS beat by 24.32%. Stock down 6.87%. Full breakdown."}}